D-ribose is a 5-carbon sugar that forms the backbone of ATP, RNA, and DNA. It's marketed for energy production and chronic fatigue, but our research shows the clinical evidence is surprisingly thin. The strongest signal comes from cardiac patients: ribose (15g/day) improved diastolic function in heart failure patients and accelerated ATP recovery in ischemic myocardium. For exercise performance in healthy athletes, the evidence is essentially negative — multiple well-designed studies show NO ergogenic benefit. The chronic fatigue/fibromyalgia data comes from a single uncontrolled pilot study. This is a case where the biochemistry (ATP precursor!) sounds more compelling than the clinical reality.
D-ribose is synthesized endogenously via the pentose phosphate pathway, but this pathway is slow (days to fully restore ATP in stressed tissues). Supplemental ribose bypasses the rate-limiting step (glucose-6-phosphate dehydrogenase) and provides the 5-carbon sugar backbone directly for ATP synthesis via the salvage pathway: ribose → ribose-5-phosphate → PRPP → AMP → ADP → ATP. In ischemic cardiac tissue, the pentose phosphate pathway is especially compromised, making exogenous ribose particularly valuable. In healthy, non-ischemic tissue, ATP levels are already maintained normally — explaining why healthy athletes don't benefit.
No critical interactions identified.
Reviewed by the Scan Dose Research Team and Clinical Advisory Board | Last updated:
Not medical advice. Based on published clinical research and systematic reviews.